Perivascular Niche–Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment

• Published in: Cancer research (Chicago, Ill.) Vol. 85; no. 11; pp. 2081 - 2099
• Main Authors: Wei, Qing, Yang, Teng, Zhang, Ziwen, Wang, Fei, Yang, Yuxuan, Zhu, Jiayu, Zhu, Xiu, Li, Yuanzheng, Xing, Yun, Lu, Ye, Tian, Xuefei, Fan, Mengyang, Zhang, Yuchao, Xue, Xiru, Li, Meng, Yu, Chuanfei, Wang, Lan, Shimura, Takaya, Fang, Jianmin, Cao, Zhiwei, Ying, Jieer, Guo, Peng, Cheng, Xiangdong
• Format: Journal Article
• Language: English
• Published: United States 02.06.2025
• Subjects: Animals; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Disease Models, Animal; Female; Humans; Immunoconjugates - adverse effects; Lung Diseases, Interstitial - chemically induced; Lung Diseases, Interstitial - immunology; Lung Diseases, Interstitial - pathology; Macrophages, Alveolar - drug effects; Macrophages, Alveolar - immunology; Macrophages, Alveolar - metabolism; Macrophages, Alveolar - pathology; Mice; Mice, Inbred C57BL; Trastuzumab - adverse effects

Trastuzumab deruxtecan (T-DXd) is a transformative HER2-targeting antibody–drug conjugate (ADC) for treating breast cancer. Unfortunately, T-DXd has also been implicated in causing fatal interstitial lung disease (ILD) in multiple clinical trials. A better understanding of the mechanistic basis of t...